Kyaw Moe H, Jones Ian G, Campbell Harry
Public Health Sciences, University of Edinburgh, UK.
Scand J Infect Dis. 2002;34(8):559-63. doi: 10.1080/00365540210147534.
Penicillin resistance of Pneumococci is a problem in several European countries. Therefore, we examined 510 invasive pneumococcal isolates, collected between 1992 and 1999 via a national network of diagnostic laboratories covering the entire population of Scotland, for penicillin susceptibility, in order to determine the prevalence, site of infection and serogroup/type distribution of penicillin-resistant Pneumococci in the elderly (> or = 65 y). Of the 510 isolates, 91.6% (n = 467) were from blood, 4.7% (n = 24) from other sterile sites and 3.7% (n = 19) from cerebrospinal fluid. The prevalence of penicillin non-susceptible isolates during the study period was 9%. An increase in the proportion of Pneumococci non-susceptible to penicillin was detected from 1996 onwards, from 10.8% in 1996 to 14.3% in 1999. There were 2 isolates with high-level penicillin resistance, both of which were of serotype 14, accounting for 4.3% (2/46) of all non-susceptible isolates. Penicillin non-susceptible isolates belonged to the following serogroups: 14 (32.6%); 9 (30.4%); 6 (19.6%); 23 (10.9%); and 19 (6.5%). The leading non-susceptible serotype/group varied according to the specimen type: serotype 14 for blood and serogroup 9 for all other sterile sites. Current polysaccharide and new 7-, 9- and 11-valent conjugate vaccine formulations included the serogroups responsible for all the penicillin non-susceptible isolates detected. Therefore vaccination represents the most effective strategy for decreasing the burden of drug resistance. Constant surveillance of the patterns of antibiotic non-susceptible isolates, the site of infection and the serogroup/type are necessary in order to select antibiotic therapy and establish vaccination policy for the prevention of invasive pneumococcal disease.
肺炎球菌对青霉素耐药是几个欧洲国家面临的一个问题。因此,我们检测了1992年至1999年间通过覆盖苏格兰全体人口的国家诊断实验室网络收集的510株侵袭性肺炎球菌分离株的青霉素敏感性,以确定老年(≥65岁)人群中耐青霉素肺炎球菌的患病率、感染部位以及血清群/型分布。在这510株分离株中,91.6%(n = 467)来自血液,4.7%(n = 24)来自其他无菌部位,3.7%(n = 19)来自脑脊液。研究期间青霉素不敏感分离株的患病率为9%。从1996年起,检测到对青霉素不敏感的肺炎球菌比例有所增加,从1996年的10.8%增至1999年的14.3%。有2株高水平耐青霉素菌株,均为14型,占所有不敏感分离株的4.3%(2/46)。青霉素不敏感分离株属于以下血清群:14(32.6%);9(30.4%);6(19.6%);23(10.9%);和19(6.5%)。主要的不敏感血清型/群因标本类型而异:血液标本中为14型,其他所有无菌部位标本中为9血清群。目前的多糖疫苗以及新的7价、9价和11价结合疫苗配方涵盖了所有检测到的青霉素不敏感分离株所对应的血清群。因此,接种疫苗是减轻耐药负担的最有效策略。持续监测抗生素不敏感分离株的模式、感染部位以及血清群/型对于选择抗生素治疗和制定预防侵袭性肺炎球菌疾病的疫苗接种政策是必要的。